Bio-Neuroscience 2027 (List) | Broadreach Global

2027

Bio-Neuroscience 2026 was over-subscribed. The 2027 edition is now open — and places remain strictly limited.

Feb 9 to 11, 2027

Amsterdam,
The Netherlands

Join the most exclusive gathering of neuroscience CEOs, investors, pharma decision-makers and innovators in the sector. Three editions in, Bio-Neuroscience has established itself as the event where the most consequential conversations in CNS drug development happen — and where deals begin.

SEE THE 2026 PROGRAM

ABOUT

Where the Business of Neuroscience Drug Development is Done.

Exceptional, curated quality | Strictly limited places | By-invitation or application

INSIGHT • ACCESS • ENGAGEMENT • IMPACT

The Premier Gathering — By Design

Bio-Neuroscience is by-invitation in character and strictly limited in size. No filler. No noise. A handpicked assembly of the sector's top CEOs, C-suite executives, managing partners, pharma heads of business development and licensing, and the most active investors in global CNS drug development — convened in a format designed for genuine interaction, not passive attendance.

The Business of Neuroscience Drug Development

This is not a scientific conference or mass access event. It is the exclusive summit where the hottest biotech founders engage the most active neuroscience investors, where pharma business development and therapeutic area heads meet emerging and growth companies, and where the capital markets, M&A, partnering, and strategic questions that shape the sector are discussed in depth. Three days. Sustained working sessions every day. Sustained, high-quality engagement.

A Unique Level of Access — Proven

Bio-Neuroscience 2026 sold out. 2025 firmly established the format. 2024 proved the concept. Participant feedback from every edition confirms what the Advisory Board already knew: there is no comparable event. If you are building, funding, or partnering in CNS neuroscience — this is your room.

PARTICIPANT COMMENTS

AT BROADREACH NEURO SUMMITS

Speaking at Bio-Neuroscience was a great experience, as I had the opportunity to share insights with a select group of peers who are passionate about neuroscience advancement. The engaging discussions combined with the interactive discussions during the breaks underscored the value of the meeting.

Craig Thompson

CEO - Cerevance

Great memories from Amsterdam Bio-Neuroscience 2024! A great boutique event and the place to be for anyone with interests in translational neuroscience. Well-balanced list of selected attendees, great in-depth discussions and plenty of time for networking. The 2025 edition is getting closer and closer, looking forward to attending again.

José L. Lanciego MD, PhD

Chair - International Brain Research Organization Pan-European Committee
Senior Scientist, CNS Gene Therapy Program
Functional Neuroanatomy of the Basal Ganglia Lab, CIMA

VISION

Breaking Down Silos — By Design
Convening translational scientists, clinicians, regulatory leaders, CEOs, pharma decision-makers and the most active investors in one curated space — and designing a program where genuine interaction, not broadcast, is the norm.

Convening the Full Value Chain of CNS Neuroscience Drug Development.
Bio-Neuroscience was built on a single conviction: the most important advances in CNS drug development happen when the right people are in the same room — with the depth, trust and time to go beyond the surface and into the real conversation.

Driving Transformational Connections and Partnering
Delivering the access, engagement and sustained discussion that creates real partnerships — for startups seeking capital and co-development, for investors building portfolios, and for pharma teams identifying the next generation of neuroscience assets.

Accelerating Value Creation Across the Sector
Providing the insight, feedback and peer engagement that founders, CEOs and decision-makers need to sharpen their thinking, validate their direction, and move faster — with confidence — in a complex and rapidly evolving field.

Ultimately, It's About Patients
Everything we do — every session, every connection, every deal that begins at Bio-Neuroscience — is oriented toward a single outcome: better therapies, delivered faster, for the patients and families living with neurological disease.

WHY NOW?

CNS Drug Development Is at an Inflection Point

Rational drug discovery is no longer aspirational — it is happening. New biomarkers, validated targets, maturing gene therapy platforms, and a new generation of RNA-based modalities are transforming what is possible in neuroscience. The tools have caught up with the ambition.

Capital Is Moving— and So Are Deals

Investor and industry interest in CNS neuroscience is surging, even as markets recalibrate. Partnerships, licenses, acquisitions and co-development deals are being structured at pace. The leaders making those decisions are in this room — and the conversations that start here become the transactions that define the sector.

The Right Moment. The Right City.

Bio-Neuroscience 2027 opens on 9 February — almost 4 weeks after the JPM Healthcare Conference, when the sector's key decision-makers are deal-focused and ready to move. Amsterdam, Europe's neuroscience capital and home to one of the world's leading neuroscience research institutes, provides the ideal setting for what comes next.

Three Editions. One Verdict

The 2024 edition established the concept. 2025 firmly confirmed Bio-Neuroscience as the leading science-business-investment meeting in the sector. 2026 was greatly over-subscribed — with outstanding feedback from every participant category. The 2027 edition is already in high demand. There has never been a better or more necessary time to be in this room.

MEET OUR ADVISORY BOARD

ADVISORY BOARD 2027

Robert Thorne

Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Andrea Soto Padilla

Business Development - Amsterdam UMC

Rita Balice-Gordon

Chief Executive Officer - Muna Therapeutics

Claire Leurent

Managing Director - AbbVie Ventures

Karen LaRochelle

SVP, Global Business Development & Strategy - Merz Therapeutics

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam Neuroscience UMC

Philip Scheltens

Head, Dementia Fund, Partner - EQT Life Sciences

Kees Been

Chief Executive Officer - Kynexis Therapeutics Inc.

Arno de Wilde

Managing Director - EQT Life Sciences

Juan Carlos Lopez

Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Bruce Leuchter

President & CEO - Neurvati Neurosciences

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

Jessica Atkinson

Chief Business Officer - VectorY Therapeutics

Christian J. Suojanen

Founder & CEO - Broadreach Global,
Chairman, Bio-Neuroscience Initiative

MEET THE SPEAKERS

BIO-NEUROSCIENCE SPEAKERS IN 2026

Here are the speakers featured at Bio-Neuroscience 2026.
Check back soon for the initial 2027 lineup of leading figures from across our sector!

Ben Deverman

Senior Director, Vector Engineering, Stanley Center for Psychiatric Research - The Broad Institute of MIT and Harvard

Tarek Samad

Senior Vice President & Global Head of Research - Lundbeck

Stefan König

CEO - Merz Therapeutics

Keno Gutierrez

General Partner - BioGeneration Ventures (BGV)

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Henrijette Richter

Managing Partner - Sofinnova Partners

Tillmann Krüger

Associate Professor, Deputy Head of Department - Psychiatry, Social Psychiatry and Psychotherapy, Head of Section of Clinical Psychology & Sexual Medicine - Hannover Medical School

Eric Finzi MD, PhD

Co-Founder - Healis Therapeutics

António Portela

CEO - BIAL

Jenny Laird

VP, Business Development Neuroscience - Eli Lilly

Marcelo Bigal

President and Chief Executive Officer - Ventus Therapeutics

Andrew Steinsapir

Director, Gene Therapy Program Lead - Deefield Management, & Acting CTO, Apertura Gene Therapy

Joao Barbosa da Silva

Investor - re.Mind Capital

Marco Weinberg

Senior Vice President, Head of Research - uniQure

Lynsey Bilsland

Managing Director of Parkinson's Virtual Biotech - Parkinson's UK

José Luís Lanciego

Chair – International Brain Research Organization (IBRO) Pan European
Committee, Head, Laboratory of Gene Therapy for Parkinson’s Disease – CIMA, University of Navarra

Giovanna Lalli

Director of Strategy & Operations - LifeArc

Marta Helena Lesko

VP, Head of Neurology and Immunology Business Development - Merck Group

Alex Bloom

Chief Technology Officer - AviadoBio

Yael Weiss

CEO - Mahzi Therapeutics

Christian Thomsen

Global External CNS Research - Boehringer Ingelheim

Karen LaRochelle

Global Head of Business Strategy and Portfolio Innovation - Merz Therapeutics

Vikas Sharma

Chief Business Officer - QurAlis

Claudia Persoon

Head of Neurospector - Amsterdam Neuroscience

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Kevin Sheridan

Joint Global Head of Healthcare Investment Banking - Jefferies LLC

Jing Wang

Co-Founder & Chief Executive Officer - Myrobalan Therapeutics

Opher Kornfeld

Director, Translational Research and Development - SPARK NS

Sander van Deventer

Co-Founder & President of R&D - VectorY Therapeutics

Niels Plath

Chief Scientific Officer - Muna Therapeutics

Marc Axel Wollmer, MD

Head of department, Department of Old Age Psychiatry - Asklepios Clinic North – Ochsenzoll

Violeta Stoyanova-Beninska

Senior Scientific Specialist, Office of Therapies for neurological and psychiatric disorders, &
Former Chair of Committee for Orphan Medicinal Products -
European Medicines Agency,
Chair of Regulatory Science Committee - International Rare Disease Research Consortium

Sven Pfeiffer

Partner, Strategic Advisory Group - PJT Partners

Pablo Sardi

Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi

Eric Stewart

Senior Managing Director, Healthcare Mergers & Acquisitions - Leerink Partners

Thomas Michael Thestrup

Senior Principal - Angelini Ventures

Richard Reschen

Director, Business Development & Licensing - MSD

Stuart Cobb

Chief Scientific Officer - Neurogene

A 3-DAY IMMERSION

2027 PROGRAM

Bio-Neuroscience 2027 is structured across three intensive days of plenary sessions, investor panels, fireside chats, pre-summit roundtables, startup pitches, and sustained networking — all in the same venue, with the same curated group.
The program is developed with the Advisory Board and reflects the sector's most pressing scientific, commercial, regulatory and financial questions.

Day I — Tuesday, 9 February 2027

Arrival & Accreditation

Pre-Summit Roundtable Sessions, Networking & Inauguration

Official Welcome Networking Reception & Dinner

Day II — Wednesday, 10 February 2027

Full-Day Program:

Keynotes & Fireside Chats

Science, Investment, Market, Pipeline and Partnering

Hosted Networking Lunch

Hosted End of End-of-DayReception & Walking Dinner

Day III — Thursday, 11 February 2027

Full-Day Program:

Keynotes & Fireside Chats

Topical Sessions on Gene Therapy, Novel Modalities, Cutting Edge Science & Breakthrough Innovations

Industry Partnering, Case Studies, Collaboration & Co-Development

Company Pitch Sessions

Bio-Neuroscience Awards & Closing Tapas & Drinks Reception

Click for the 2026 Program

Note: The full 2026 Program is available by clicking the orange button on the See 2026 Program button to the right. The 2027 program will be announced mid - summer 2026.

WHO YOU'LL MEET?

EXCLUSIVE ACCESS TO THE NEUROSCIENCE DRUG DEVELOPMENT DECISION-MAKING COMMUNITY

Over three days of high-level plenary sessions, interactive roundtables, networking, hosted lunches and receptions — one curated group, sustained engagement.

FOUNDERS & CEOS

Founders, CEOs and C-level executives from the most innovative CNS neuroscience biotech companies in the sector. The builders of tomorrow's therapies.

INVESTORS

Managing Partners, Partners, Managing Directors and Directors from the most active CNS-focused VC funds, corporate venture arms, private equity firms, family offices, and philanthropic foundations. The capital behind the science.

KEY OPINION LEADERS

Leading translational scientists, clinicians, regulatory experts, biomarker specialists, and clinical development leaders contributing the scientific and clinical context that grounds the business discussion.

GOVERNMENT, NGOs & PATIENT ORGANIZATIONS

Public funding bodies, policy makers, regulatory bodies, disease foundations, patient-driven organizations and research consortia representing the full value chain of CNS drug development.

INDUSTRY LEADERS

Heads of Therapeutic Area, Business Development & Licensing, Alliance Management, Strategy, Portfolio Innovation and Scouting from pharma and large biotech. The buyers, collaborators and partners.

CAPITAL MARKETS & M&A

Investment banking, M&A advisory, and strategic advisory leaders from the sector's top banks and firms — providing the financial market intelligence that shapes deal-making strategy.

WHO YOU'LL MEET

PARTICIPANTS REGULARLY INCLUDE

EVENT REGISTRATION INFO

Join the most exclusive gathering of neuroscience CEOs, investors, pharma decision-makers and innovators in the sector.

PRESENT YOUR COMPANY

TO THE SECTOR'S TOP INVESTORS AND DECISION-MAKERS

Bio-Neuroscience offers a small number of highly innovative CNS-focused startups and growth-stage companies the opportunity to present in the main plenary session — in front of the full audience, not tucked into a side room.
Selection is by merit and scientific/commercial potential. There is no pay-to-play.

Pre-summit guidance and feedback on your deck.

A pre-summit dry-run presentation with feedback.

5 minute presentation followed by 5 minutes Q&A with an expert panel of relevant investors and industry: In front of the full audience in the plenary session - not off in some side room!

Post Pitch Meetings

Post Pitch Meeting space to continue your Q&A, in the networking break immediately following your session.

Network Engagement

Full access to two days of sustained engagement with investors, pharma therapeutic area and BD&L leaders, and industry decision-makers across the entire summit

Exclusive Poster Display - Presenting Companies Only

Optional: dedicated poster stand to maximize visibility. For avoidance of any confusion, posters are not required and this option has no impact on selection for presentation.

VENUE

HOTEL JAKARTA, AMSTERDAM

Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in Neuroscience drug development.

HOTEL JAKARTA

Javakade 766, 1019 SH Amsterdam, Netherlands

Bio-Neuroscience 2027 returns to Hotel Jakarta — Amsterdam's most distinctive sustainable waterfront hotel, designed as a green oasis on the IJ river.
The venue was deliberately chosen for the way it works: intimate enough to foster genuine interaction, spacious enough for three days of ambitious programming and networking. Excellent natural light, a dedicated plenary space, and superior networking areas — purpose-suited to the boutique, high-intensity format of Bio-Neuroscience.